Just two years after its founding, Alnara Pharmaceuticals Inc. agreed to be acquired by Eli Lilly and Co. (BioWorld Today)

As Pfizer Inc. suspended development of a massive clinical program for osteoarthritis pain, the question on every biotech's lips likely was whether the antibody, tanezumab, or the target, nerve growth factor (NGF), was at fault. (BioWorld Today)

Regulus Therapeutics Inc. landed its biggest partnership to date: a $750 million deal with Sanofi-Aventis Group SA aimed at discovering microRNA-based drugs against four fibrosis targets. (BioWorld Today)